Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Aug 11

PMID 27508300

Authors

Markus Alexander Thaler

Regina Feurer

Christoph Thaler

Natalie Sonntag

Michael Schleef

Ina-Christine Rondak

Holger Poppert

Affiliations

Soon will be listed here.

Abstract

Background: Activated protein C (APC) resistance is the most common inherited prothrombotic disorder. The role of APC resistance in ischemic stroke is controversially discussed.

Objectives: The aim of this single center follow up study was to investigate the effect of APC resistance on stroke recurrence and survival in stroke patients.

Patients/methods: We retrospectively identified 966 patients who had had an ischemic stroke or transitory ischemic attack (TIA) and in whom laboratory tests for APC resistance had been conducted. These patients were contacted to determine the primary outcomes of recurrent ischemic stroke or death.

Results: A total of 858 patients with an average follow up time of 8.48 years were included. APC resistance did not influence cumulative incidence functions for stroke free and total survival. In multivariate analyses, crude and adjusted hazard ratios for recurrent stroke as well as for death where not significantly increased in patients with APC resistance. This also applies to the subgroups of young patients, patients with cryptogenic stroke and patients with atrial fibrillation.

Conclusion: APC-resistance is not a risk factor for subsequent stroke or death in patients with a first ischemic stroke or TIA. Testing for APC-resistance in stroke patients therefore cannot be routinely recommended.

References

Supanc V, Sonicki Z, Vukasovic I, Solter V, Zavoreo I, Kes V . The role of classic risk factors and prothrombotic factor gene mutations in ischemic stroke risk development in young and middle-aged individuals. J Stroke Cerebrovasc Dis. 2013; 23(3):e171-6. DOI: 10.1016/j.jstrokecerebrovasdis.2013.09.025. View

Grossmann R, Geisen U, Merati G, Mullges W, Schambeck C, Walter U . Genetic risk factors in young adults with 'cryptogenic' ischemic cerebrovascular disease. Blood Coagul Fibrinolysis. 2002; 13(7):583-90. DOI: 10.1097/00001721-200210000-00002. View

Adams Jr H, Bendixen B, Kappelle L, Biller J, Love B, Gordon D . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1):35-41. DOI: 10.1161/01.str.24.1.35. View

Hamedani A, Cole J, Cheng Y, Sparks M, OConnell J, Stine O . Factor V leiden and ischemic stroke risk: the Genetics of Early Onset Stroke (GEOS) study. J Stroke Cerebrovasc Dis. 2011; 22(4):419-23. PMC: 3288467. DOI: 10.1016/j.jstrokecerebrovasdis.2011.10.007. View

Pezzini A, Grassi M, Del Zotto E, Archetti S, Spezi R, Vergani V . Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults. Stroke. 2005; 36(3):533-9. DOI: 10.1161/01.STR.0000155741.31499.c2. View

Rey R, de Larranaga G, Lepera S, Cohen M, Saposnik G, Alonso B . Activated protein C resistance in patients with arterial ischemic stroke. J Stroke Cerebrovasc Dis. 2007; 10(3):128-31. DOI: 10.1053/jscd.2001.25464. View

Lalouschek W, Schillinger M, Hsieh K, Endler G, Tentschert S, Lang W . Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke. 2005; 36(7):1405-9. DOI: 10.1161/01.STR.0000170635.45745.b8. View

Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone A, Orefice G . Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke. 2002; 33(1):51-6. DOI: 10.1161/hs0102.100483. View

Moskau S, Smolka K, Semmler A, Schweichel D, Harbrecht U, Muller J . Common genetic coagulation variants are not associated with ischemic stroke in a case-control study. Neurol Res. 2009; 32(5):519-22. DOI: 10.1179/016164109X12464612122533. View

10.

Weber R, BUSCH E . [Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment]. Nervenarzt. 2004; 76(2):193-201. DOI: 10.1007/s00115-004-1789-1. View

11.

Austin H, Chimowitz M, Hill H, Chaturvedi S, Wechsler L, Wityk R . Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke. 2002; 33(12):2762-8. DOI: 10.1161/01.str.0000038094.79901.3b. View

12.

Kheradmand E, Pourhossein M, Amini G, Saadatnia M . Factor V Leiden does not have a role in cryptogenic ischemic stroke among Iranian young adults. Adv Biomed Res. 2014; 3:80. PMC: 3988598. DOI: 10.4103/2277-9175.127993. View

13.

Yaghi S, Elkind M . Cryptogenic stroke: A diagnostic challenge. Neurol Clin Pract. 2014; 4(5):386-393. PMC: 4196459. DOI: 10.1212/CPJ.0000000000000086. View

14.

de Lau L, Leebeek F, de Maat M, Koudstaal P, Dippel D . Screening for coagulation disorders in patients with ischemic stroke. Expert Rev Neurother. 2010; 10(8):1321-9. DOI: 10.1586/ern.10.104. View

15.

Voetsch B, Damasceno B, Camargo E, Massaro A, Bacheschi L, Scaff M . Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost. 2000; 83(2):229-33. View

16.

Rosendaal F, Koster T, Vandenbroucke J, Reitsma P . High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995; 85(6):1504-8. View

17.

Bertina R, Koeleman B, Koster T, Rosendaal F, Dirven R, de Ronde H . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64-7. DOI: 10.1038/369064a0. View

18.

Bushnell C, Datta S, Goldstein L . Cost implications of specialized coagulation testing for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2007; 10(6):279-83. DOI: 10.1053/jscd.2001.123777. View

19.

Bushnell C, Goldstein L . Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke. 2000; 31(12):3067-78. DOI: 10.1161/01.str.31.12.3067. View

20.

Dragoni F, Chiarotti F, Rosano G, Simioni P, Tormene D, Mazzucconi M . Thrombophilic screening in young patients (< 40 years) with idiopathic ischemic stroke: a controlled study. Thromb Res. 2010; 127(2):85-90. DOI: 10.1016/j.thromres.2010.11.013. View